Orforglipron and tirzepatide are both metabolic compounds in the incretin space, but they differ in what they target, how they are made, and how far along they are. Orforglipron is a non-peptide small molecule that acts on GLP-1 only and is taken as a once-daily pill. Tirzepatide is an injectable peptide that targets both GLP-1 and GIP, and it is FDA-approved under the brands Mounjaro and Zepbound.
Reviewed for accuracy · Last reviewed July 8, 2026The starkest difference is regulatory and structural. Tirzepatide is an FDA-approved injectable peptide with a defined labeled titration and Phase 3 evidence. Orforglipron is an oral small molecule that had completed its Phase 3 program and was under FDA review as of 2026, so it did not yet carry an approved label at that time. Verify its current status with an authoritative source.
Mechanistically, tirzepatide adds the GIP receptor to the GLP-1 target, making it a dual agonist, whereas orforglipron acts on GLP-1 alone. Whether that mechanistic difference translates into a meaningful real-world gap is not something cross-trial comparisons can establish as fact. The clearer everyday contrast is a once-daily pill versus a once-weekly injection that involves reconstitution when sourced as a vial.
Both reported mostly gastrointestinal side effects that were dose-related and concentrated during escalation. Tirzepatide additionally carries a labeled boxed warning for thyroid C-cell tumors seen in rodents, a caution that applies broadly across this receptor class. Neither summary is a substitute for medical advice about which, if either, is appropriate.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.